Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery.
NephroDI Therapeutics, MSRD partner to develop therapy for NDI
NephroDI Therapeutics’ NDI-5001 is being developed to treat X-linked congenital nephrogenic diabetes insipidus, a rare genetic kidney condition. Credit: crystal light / Shutterstock.com. NephroDI Therapeutics